 Many Huntington disease<disease> ( HD) mutation carriers already have cognitive and psychiatric symptoms<symptom> in the premanifest ( premotor) phase of the disease<disease> , but the molecular underpinnings of these symptoms<symptom> are not well understood. Previous work has shown reduced availability of the cerebral type 1 cannabinoid receptor ( CB